GENELUX Corp $GNLX

What the company doesAI summary of filing

Genelux is a late-stage biopharmaceutical company developing oncolytic viral immunotherapies based on modified vaccinia virus for patients with aggressive or difficult-to-treat cancers. The company's lead product candidate, Olvi-Vec, is being evaluated in three ongoing clinical trials: a Phase 3 registrational trial for platinum-resistant ovarian cancer in the United States, a Phase 2 trial for recurrent non-small cell lung cancer in the United States, and a Phase 1b/2 trial for recurrent small cell lung cancer in China conducted with partner Newsoara. Genelux operates a cGMP manufacturing facility in San Diego, California and generates revenue through development milestone and royalty payments from its licensing agreement with Newsoara, having received $11.0 million to date with potential for up to $160.5 million in additional milestone payments. [10-K 2026-03-19]

Segments: Olvi-Vec (platinum-resistant ovarian cancer), Olvi-Vec (non-small cell lung cancer), Olvi-Vec (small cell lung cancer), CHOICE platform (oncolytic virus discovery)